Exelixis, Inc. (EXEL)

Market Cap	12.23B
Revenue (ttm)	2.30B
Net Income (ttm)	643.57M
Shares Out	272.71M
EPS (ttm)	2.20
PE Ratio	20.36
Forward PE	18.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,063,673
Open	45.00
Previous Close	45.17
Day's Range	44.77 - 45.41
52-Week Range	22.13 - 49.62
Beta	0.28
Analysts	Buy
Price Target	43.65 (-2.7%)
Earnings Date	Aug 5, 2025

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,147
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Analyst Summary

According to 18 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $43.65, which is a decrease of -2.70% from the latest price.

Price Target

$43.65

(-2.70% downside)

Analyst Consensus: Buy